25 unknown. 25 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 25 | Unknown 25 |
Follow Bioequivalence: new trials by email Literature Review of Bioequivalence trials Research Report on Bioequivalence
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Bioequivalence Study of Perindopril Tablets in Healthy Volunteers Under Fasting Conditions Perindopril tablet, Prestarium® A tablet - Bioequivalence | Phase 1 | Unknown | Pharmtechnology LLC | 50 | 2024-01-09 | 2024-01-19 |
| Study on the Bioequivalence of Amisulpride Orally Disintegrating Tablets in Human Body Drug: Test (T) Amisulpride orally disintegrating tablets (200mg). Produced and supplied by Zezheng (Shanghai) Biotechnology Co., Ltd. - Bioequivalence, Schizophrenia | Phase 1 | Unknown | The Affiliated Hospital of Qingdao University | 100 | 2023-09-20 | 2023-10-04 |
| Bioequivalence Study for Fluticasone Propionate 500 mcg/Salmeterol Xinafoate 50 mcg Inhalation Powder in Healthy Volunteers Fluticasone propionate 500 mcg and salmeterol xinafoate 50 mcg/Respirent Pharmaceuticals, ADVAIR DISKUS® 500/50 - Bioequivalence | Phase 1 | Unknown | Respirent Pharmaceuticals Co Ltd. | 34 | 2023-08-22 | 2023-09-06 |
| Bioequivalence Study for Fluticasone Propionate 250 mcg/Salmeterol Xinafoate 50 mcg Inhalation Powder in Healthy Volunteers Fluticasone propionate 250 mcg and salmeterol xinafoate 50 mcg/Respirent Pharmaceuticals, ADVAIR DISKUS® 250/50 - Bioequivalence | Phase 1 | Unknown | Respirent Pharmaceuticals Co Ltd. | 34 | 2023-08-01 | 2023-08-31 |
| Bioequivalence Study of Perindopril /Amlodipine/Indapamide 8 mg (10 mg)/2.5 mg/10 mg Tablets in Healthy Volunteers Under Fasting Conditions Perindopril/Indapamide/Amlodipine 8 mg/2.5 mg/10 mg tablet / Triplixam® 10 mg/2.5 mg/10 mg tablet - Bioequivalence | Phase 1 | Unknown | Pharmtechnology LLC | 50 | 2023-06-24 | 2023-07-11 |
| Bioequivalence Study for Fluticasone Propionate 100 mcg/Salmeterol Xinafoate 50 mcg Inhalation Powder in Healthy Volunteers Fluticasone propionate 1000 mcg and salmeterol xinafoate 50 mcg/Respirent Pharmaceuticals, ADVAIR DISKUS 100/50 - Bioequivalence | Phase 1 | Unknown | Respirent Pharmaceuticals Co Ltd. | 34 | 2023-02-17 | 2023-03-09 |
| Bioequivalence Study of Sulfadoxine/ Pyrimethamine Dispersible Tablets in Healthy Subjects Under Fasting Conditions Sulfadoxine/Pyrimethamine dispersible tablets, 250 mg sulfadoxine / 12.5 mg pyrimethamine & 500 mg sulfadoxine / 25 mg pyrimethamine, G-COSPE® tablets - Bioequivalence | Phase 1 | Unknown | Emzor Pharmaceutical Industries Limited | 70 | 2022-12-01 | 2022-08-11 |
| Double-blind, Randomized Comparative Cross-sectional Study of Pharmacodynamics and Pharmacokinetics of Drugs GP40141 GP40141, Nplate - Pharmacodynamics, Pharmacokinetics | Phase 1 | Unknown | Geropharm | 56 | 2022-06-03 | 2022-12-15 |
| A Study Comparing Two Different Capsules, APL-101 and PLB-1001 Capsules, in Healthy Chinese and Caucasian Participants APL-101, PLB-1001 - Bioequivalence | Phase 1 | Unknown | Apollomics Inc. | 48 | 2022-05-20 | 2022-06-15 |
| A Bioequivalence Study Between Fluticasone Propionate 250 mcg/Blister Oral Inhalation Powder/Respirent Pharmaceuticals vs. FLOVENT DISKUS® 250 mcg/Blister Oral Inhalation Powder /GSK in Healthy Volunteers Under Fasting Conditions Fluticasone Propionate 250 mcg/Blister Oral Inhalation Powder/Respirent Pharmaceuticals, FLOVENT DISKUS - Asthma, Bioequivalence | Phase 1 | Unknown | Respirent Pharmaceuticals Co Ltd. | 36 | 2022-05-11 | 2022-05-31 |
| A Bioequivalence Trial of Irbesartan Tablets（0.15g） in Healthy Chinese Subjects Irbesartan Tablet - Irbesartan Tablets (0.15g/Tablet), Under Fasted Condition | Phase 1 | Unknown | The Affiliated Hospital of Qingdao University | 54 | 2022-02-17 | 2022-03-28 |
| The Bioequivalence Study of Two Sunitinib Products in Capsules 50 mg in Healthy Volunteers Under Fasting Conditions Aviga, capsules 50 mg / Sutent®, capsules 50 mg, Sutent®, capsules 50 mg / Aviga, capsules 50 mg - Bioequivalence | Phase 1 | Unknown | JLLC NatiVita | 22 | 2022-01-21 | 2022-02-01 |
| Bioequivalence Study of Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 250/50 Inhalation Powder/GSK in Healthy Volunteers Test, Reference - Bioequivalence, Asthma | Phase 1 | Unknown | Respirent Pharmaceuticals Co Ltd. | 18 | 2021-10-01 | 2021-10-20 |
| A Bioequivalence Study Between Fluticasone Propionate 100 mcg/Blister Oral Inhalation Powder/Respirent Pharmaceuticals vs. FLOVENT DISKUS® 100 mcg/Blister Oral Inhalation Powder /GSK in Healthy Volunteers Under Fasting Conditions Fluticasone Propionate 100 mcg/Blister Oral Inhalation Powder/Respirent Pharmaceuticals, FLOVENT DISKUS - Asthma, Bioequivalence | Phase 1 | Unknown | Respirent Pharmaceuticals Co Ltd. | 50 | 2021-08-13 | 2021-08-26 |
| Bioequivalence Study of Two Formulations of Sildenafil Tablet 100 mg in Healthy Male Volunteers Under Fasting Conditions Sildenafil film-coated tablet 100 mg, Viagra® film-coated tablet 100 mg - Bioequivalence | Phase 1 | Unknown | Pharmtechnology LLC | 44 | 2021-05-10 | 2021-05-12 |
| Bioequivalence Study of Two Formulations of Etoricoxib Tablets 120 mg in Healthy Volunteers Under Fasting Conditions Etoricoxib film-coated tablet 120 mg, Arcoxia® film-coated tablet 120 mg - Bioequivalence | Phase 1 | Unknown | Pharmtechnology LLC | 34 | 2021-04-10 | 2021-04-05 |
| Bioequivalence Study of Two Formulations of Rivaroxaban Tablets 10 mg in Healthy Male Volunteers in Fasting Conditions Rivaroxaban film-coated tablet 10 mg, Xarelto® film-coated tablet 10 mg - Bioequivalence | Phase 1 | Unknown | Pharmtechnology LLC | 34 | 2021-02-13 | 2021-02-15 |
| Bioequivalence Study of Two Formulations of Rivaroxaban Tablets 20 mg in Healthy Male Volunteers Under Fed Conditions Rivaroxaban film-coated tablet 20 mg, Xarelto® film-coated tablet 20 mg - Bioequivalence | Phase 1 | Unknown | Pharmtechnology LLC | 34 | 2021-01-30 | 2021-01-29 |
| A Bioequivalence Study Between Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 250/50 Inhalation Powder/GSK in Healthy Volunteers Test, Reference - Bioequivalence, Asthma | Phase 1 | Unknown | Respirent Pharmaceuticals Co Ltd. | 50 | 2021-01-18 | 2021-04-20 |
| Bioequivalence Study of Sulfadoxine/ Pyrimethamine Tablets in Healthy Subjects Under Fasting Conditions Maldox tablets, G-COSPE® tablets - Bioequivalence | Phase 1 | Unknown | Emzor Pharmaceutical Industries Limited | 52 | 2020-12-01 | 2020-10-08 |
Showing 20 of 25. Sign in to see all of them.
Asthma (4) · Schizophrenia (1)
Bronchial Diseases (4) · Hypersensitivity (4) · Hypersensitivity, Immediate (4) · Immune System Diseases (4) · Lung Diseases (4) · Lung Diseases, Obstructive (4) · Respiratory Hypersensitivity (4) · Respiratory Tract Diseases (4) · Mental Disorders (1) · Schizophrenia Spectrum and Other Psychotic Disorders (1)
Fluticasone (7) · Salmeterol Xinafoate (5) · Drug Evaluation (2) · Perindopril (2) · Amisulpride (1) · Amlodipine (1) · Angptl4 protein, mouse (1) · Capsules (1) · Hydrochlorothiazide (1) · Indapamide (1) · Irbesartan (1) · Long-Term Synaptic Depression (1) · Motion Pictures (1) · Olmesartan Medoxomil (1) · Postprandial Period (1)
Pharmtechnology LLC (7) · Respirent Pharmaceuticals Co Ltd. (7) · Emzor Pharmaceutical Industries Limited (2) · The Affiliated Hospital of Qingdao University (2) · Apollomics Inc. (1) · Atabay Kimya Sanayi Ticaret A.S. (1) · CSPC ZhongQi Pharmaceutical Technology Co., Ltd. (1) · Geropharm (1) · JLLC NatiVita (1) · Jiangsu HengRui Medicine Co., Ltd. (1) · Pharma Plant (1)
Greece (7) · Russia (7) · China (3) · Turkey (Türkiye) (2) · Belarus (1) · Canada (1) · New Zealand (1)
Chrysoula Doxani, MD, MSc, PhD (5) · Alexander Khokhlov (4) · Muradiye Nacak, MD,PhD (2) · Taner Ezgi, MD (2) · Chrysoula Doxani, Dr. (1) · Eric Sicard, MD (1) · Igor Mr Makarenko, PhD (1) · Ioannis Stefanidis, Professor (1) · Irina Rodyukova (1) · Marietta Franco, MS (1) · Mohammed A Abu Fara, MD,Internist (1) · Yu Cao, professor (1)